Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.78 |
| ▸ | ACHE | P22303 | 3/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | HPGD | P15428 | 2/20 | 0.78 |
| ▸ | HTR2C | P28335 | 2/20 | 0.78 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.78 |
| ▸ | CDK1 | P06493 | 2/20 | 0.78 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.78 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.78 |
| ▸ | CDK2 | P24941 | 2/20 | 0.78 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.78 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.78 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.78 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6123447 | 0.90 | MAOA (0.68) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL30510974 | 0.88 | MAOA (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL29440552 | 0.88 | MAOA (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL29941920 | 0.88 | MAOA (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL9481427 | 0.88 | MAOA (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL292955 | 0.88 | MAOA (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL1469013 | 0.87 | KLK7 (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL30726913 | 0.87 | KLK7 (1.00) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL16099771 | 0.87 | MAOA (0.97) | MAOADYRK1AKDM4EALDH1A1HSD17B10 | |
| Harmine SCHEMBL31500130 | 0.85 | KLK7 (0.97) | MAOADYRK1AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117705184-A | Detection method for chemical components of anemone-resistant tung tree | 中国热带农业科学院热带作物品种资源研究所 | 2024-03-15 | — | — | CN | claimed |
| US-20250171749-A1 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | Empyrean Neuroscience, Inc. | 2025-05-29 | — | — | US | disclosed |
| EP-4457336-A2 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | Empyrean Neuroscience, Inc. (US) | 2024-11-06 | — | — | EP | disclosed |
| CN-118787686-A | Diabetes treating medicine and its prepn | 杨志岐 | 2024-10-18 | — | — | CN | disclosed |
| US-12104179-B2 | Genetically modified organisms for producing psychotropic alkaloids | Empyrean Neuroscience, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| CN-116751197-B | Carbolin alkaloid or pharmaceutically acceptable salt thereof, preparation method and application thereof, and carbolin alkaloid pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2024-04-12 | — | — | CN | disclosed |
| US-20240101976-A1 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | Empyrean Neuroscience, Inc. | 2024-03-28 | — | — | US | disclosed |
| CN-117705184-A | Detection method for chemical components of anemone-resistant tung tree | 中国热带农业科学院热带作物品种资源研究所 | 2024-03-15 | — | — | CN | disclosed |
| US-20240009332-A1 | COMPOSITE EMBOLIZATION BEADS | TRANSLATIONAL AND FUNDAMENTAL TECHNOLOGIES INSTITUTE LLC | 2024-01-11 | — | — | US | disclosed |
| US-20230398166-A1 | METHOD FOR EXTRACTING A FULL SPECTRUM OF HYDROPHILIC COMPOUNDS FROM BIOMASS | TUDELA JERRED (US) | 2023-12-14 | — | — | US | disclosed |
| US-7429397-B2 | Herbal formulation as memory enhancer in Alzheimer condition | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2008-09-30 | — | — | US | disclosed |
| EP-1567177-B1 | MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES | PHYTRIX AG (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070042054-A1 | FUNCTIONAL APHRODISIAC ROLLED HERBAL BIDIS AND CIGARETTES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2007-02-22 | — | — | US | disclosed |
| WO-2006111830-A2 | FUNCTIONAL APHRODISIAC ROLLED HERBAL BIDIS AND CIGARETTES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-10-26 | — | — | WO | disclosed |
| US-20060165822-A1 | Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases | PHYTRIX AG (DE) | 2006-07-27 | — | — | US | disclosed |
| US-20060141068-A1 | Herbal formulation as memory enhancer in alzheimer condition | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2006-06-29 | — | — | US | disclosed |
| WO-2006067796-A1 | HERBAL FORMULATION AS MEMORY ENHACHER IN ALZHEIMER CONDITION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-06-29 | — | — | WO | disclosed |
| EP-1567177-A2 | MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES | Phytrix AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004039385-A2 | MUCUNA PRURIENS AND EXTRACTS THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES | PHYTRIX AG (DE) | 2004-05-13 | — | — | WO | disclosed |
| US-20010056085-A1 | Methods of using vesicant drug formulations | RAMU AVNER (US) | 2001-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056085-A1 | Methods of using vesicant drug formulations | UGT1A1, SLC47A1, UGT1A10 | MAOA 1710/4885DYRK1A 3504/4885KDM4E 2544/4885 |
| US-20250171749-A1 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | PNMT, INMT, AANAT | MAOA 5/4885DYRK1A 569/4885KDM4E 754/4885 |
| US-20240101976-A1 | GENETICALLY MODIFIED ORGANISMS FOR PRODUCING PSYCHOTROPIC ALKALOIDS | PNMT, INMT, AANAT | MAOA 5/4885DYRK1A 569/4885KDM4E 754/4885 |
| US-12104179-B2 | Genetically modified organisms for producing psychotropic alkaloids | PNMT, INMT, AANAT | MAOA 5/4885DYRK1A 569/4885KDM4E 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.